Drug Trial Radar · NCT06059391
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
216
Planned (sponsor's estimate)
Start
Jul 9, 2024
Primary completion
Jan 1, 2027
Study completion Jan 1, 2028
Sponsor
- Lead sponsor
- City of Hope Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Sep 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. The CMV-MVA Triplex vaccine works by causing an immune response in the donors body to the CMV virus, creating immunity to it. The donor then passes that immunity on to the patient upon receiving the stem cell transplant. Giving the CMV-MVA triplex vaccine to donors may help prevent CMV infection of patients undergoing stem cell transplantation.
Conditions
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Hematopoietic and Lymphoid System Neoplasm
- Hodgkin Lymphoma
- Myelodysplastic Syndrome
- Myelofibrosis
- Myeloproliferative Neoplasm
- Non-Hodgkin Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell TransplantationProcedure
Undergo HCT with donor peripheral blood stem cells
Biospecimen CollectionProcedure
Undergo blood sample collection
Granulocyte Colony-Stimulating FactorDrug
Undergo stem cell mobilization with G-CSF
Hematopoietic Cell Transplantation Conditioning RegimenDrug
Receive pre transplant conditioning
Multi-peptide CMV-Modified Vaccinia Ankara VaccineBiological
Given IM
PheresisProcedure
Undergo apheresis
Placebo AdministrationDrug
Given IM
Stem Cell Mobilization TherapyDrug
Undergo stem cell mobilization with G-CSF
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time from transplantation to cytomegalovirus (CMV) disease or pre-emptive treatment following CMV reactivation (efficacy)Time frame: From hematopoietic stem cell transplantation (HCT) to day 180
- Occurrence of non-relapse mortality (safety in HCT-recipients)Time frame: Up to day 100 post HCT
- Incidence of severe acute graft versus host disease (aGHVD) (safety in HCT-recipients)Time frame: Up to 100 days post HCT
- Incidence of severe adverse events (AEs) (safety in HCT-recipients)Time frame: Within 2 weeks from transplantation and up to 1 year post HCT
- Incidence of grade 3 and higher AEs (safety in HCT-donors)Time frame: Within 14 days
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Medical Center
Duarte, California · Recruiting
Northside Hospital
Atlanta, Georgia · Recruiting
DFCI/BWH Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.